ACXP earnings analysis
What we found in ACXP's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q text does not include the quarterly income statement, balance sheet, cash-flow statement, segment data, or MD&A detail needed to calculate revenue, margins, EPS, or free cash flow. Financially, the filing reports approximately $10.7 million of cash at June 30, 2026, a six-month net loss of $3.9 million, and states that existing resources will not fund operations for at least 12 months. The going-concern disclosure, continued reliance on equity financing, and updated Nasdaq market-value rule create a more negative risk profile despite continued Phase 2b development of ibezapolstat.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Cash Increased Following April Financing
- Cash was approximately $10.7 million as of June 30, 2026, compared with approximately $9.3 million cited in the prior Q1 analysis. The company also raised approximately $2.3 million of net proceeds in an April 2026 registered direct offering and concurrent private placement.
- Six-Month Loss Reached $3.9 Million
- The company reported a net loss of $3.9 million for the six months ended June 30, 2026, versus $8.0 million for the full year ended December 31, 2025. The filing states that losses are expected to continue as clinical and regulatory development progresses.
- Phase 2b Supply Described as Sufficient
- Acurx continues development of ibezapolstat for CDI, including a Phase 2b clinical trial. The filing states that the company currently has sufficient drug substance supply to complete the Phase 2b trial.
- Additional Equity Funding Secured
- The company raised approximately $7.8 million of net proceeds under its equity line of credit as of June 30, 2026, and approximately $2.3 million from the April 2026 financing.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Runway Is Less Than 12 Months
- Management states that existing capital resources will not be sufficient to fund anticipated operations for at least 12 months from issuance of the June 30, 2026 financial statements. The company had approximately $10.7 million of cash at June 30, 2026 and no committed source of additional capital.
- Going-Concern Risk Remains
- The company reported net losses of $3.9 million for the six months ended June 30, 2026 and $8.0 million for fiscal 2025, while generating no product-sale revenue. The filing says the independent registered public accounting firm expressed substantial doubt about the company’s ability to continue as a going concern.
- Nasdaq Listing Risk Updated
- Nasdaq’s new rule requires listed companies to maintain market value of listed securities of at least $5 million; falling below that level for 30 consecutive business days can trigger suspension and delisting proceedings. The SEC stayed the new requirement on July 29, 2026, but the filing warns that failure to satisfy listing requirements could impair liquidity and future financing.
- Single-Source Manufacturing Exposure
- Acurx relies on third parties for manufacturing and currently sources drug substance and drug product from Piramal Pharma Solutions facilities in Ennore and Ahmedabad, India. The filing states that the company has no long-term supply agreements and has not yet sourced a backup supplier.
- Dependence on Ibezapolstat
- The company’s business is substantially dependent on ibezapolstat, its lead product candidate for CDI, and has no products approved for commercial sale. The filing states that the company has never generated revenue from product sales.
- Expanding Data-Protection Obligations
- The filing highlights expanded privacy and data-protection exposure, including potential GDPR penalties of up to €20 million or 4% of worldwide revenue and UK GDPR penalties of up to £17.5 million or 4% of worldwide revenue.
What they said about what is next.
No explicit numeric revenue or EPS guidance is provided in the supplied 10-Q text. Management states that existing capital resources will not be sufficient to fund anticipated operations for at least 12 months from issuance of the June 30, 2026 financial statements.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 11, 2026
- Acurx Pharmaceuticals reported significant operational progress during Q1 2026, with a net loss of $1.7 million, which represents a 22% reduction from $2.1 million in Q1 2025. The company continues to operate with no…
- 10-K · March 12, 2026
- Acurx (ACXP) is a late-stage biotech developing a novel DNA pol IIIC inhibitor (ibezapolstat) for C. difficile and other Gram‑positive infections; Phase 2 data show strong efficacy and favorable microbiome effects but…
- 10-Q · November 13, 2023
- Acurx reported a Q3 2023 net loss of $(3,114,981) (loss per share $(0.24)), an improvement versus Q3 2022 net loss of $(3,541,594) (loss per share $(0.32)). Cash fell to $7,052,329 at September 30, 2023 from $9,111,751…
- 10-Q · August 11, 2023
- Acurx reported a Q2 net loss of $3,445,240 (loss per share $0.28) versus a Q2 2022 loss of $2,620,533 (loss per share $0.26), driven by higher R&D spend and stable G&A. Cash ended the quarter at $9,145,835 after a…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ACXP makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever